Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

European Commission Clarifies Excipient Labeling Requirements

  • Post author:Sam
  • Post published:March 5, 2018
  • Post category:Drug Industry Daily

The European Commission issued revised guidance for regulatory authorities, marketing authorization applicants and holders on the listing of excipients on product labeling and package leaflets. Source: Drug Industry Daily

Continue ReadingEuropean Commission Clarifies Excipient Labeling Requirements

Oregon Bill on Drug Transparency Heads to Governor’s Desk

  • Post author:Sam
  • Post published:March 5, 2018
  • Post category:Drug Industry Daily

Oregon’s Senate advanced legislation that would introduce a drug cost and price transparency program, sending it to Gov. Kate Brown (D) for signature. Source: Drug Industry Daily

Continue ReadingOregon Bill on Drug Transparency Heads to Governor’s Desk

Korean Drugmaker Draws FDA Warning for Validation, Stability Issues

  • Post author:Sam
  • Post published:March 2, 2018
  • Post category:Drug Industry Daily

The FDA served Korean drug manufacturer Nowcos a warning letter after an inspection revealed multiple validation deficiencies and inadequate stability studies. Source: Drug Industry Daily

Continue ReadingKorean Drugmaker Draws FDA Warning for Validation, Stability Issues

FDA, DOJ File Complaint Against Arkansas Compounder Following GMP Deviations

  • Post author:Sam
  • Post published:March 2, 2018
  • Post category:Drug Industry Daily

Following FDA inspections and a warning letter, the Department of Justice filed a civil complaint against the outsourcing facility Cantrell Drug Company, of Little Rock, Arkansas seeking a preliminary injunction…

Continue ReadingFDA, DOJ File Complaint Against Arkansas Compounder Following GMP Deviations

Valeant Unit to Pay $58 Million to Settle Allegations of Solodyn Pay-for-Delay Scheme

  • Post author:Sam
  • Post published:March 2, 2018
  • Post category:Drug Industry Daily

A Valeant Pharmaceuticals unit agreed to pay $58 million to settle multi-district litigation that accused it of violating antitrust laws to keep generic versions of Solodyn off the market. Source:…

Continue ReadingValeant Unit to Pay $58 Million to Settle Allegations of Solodyn Pay-for-Delay Scheme

Sessions Tells DEA to Consider Lowering Opioid Production Quotas

  • Post author:Sam
  • Post published:March 2, 2018
  • Post category:Drug Industry Daily

Attorney General Jeff Sessions directed the Drug Enforcement Agency to evaluate the possibility of lowering caps on opioid production for drugmakers. Source: Drug Industry Daily

Continue ReadingSessions Tells DEA to Consider Lowering Opioid Production Quotas

Cardiologist Pleads Guilty to Giving Aegerion Patient Information to Boost Prescriptions

  • Post author:Sam
  • Post published:March 1, 2018
  • Post category:Drug Industry Daily

A pediatric cardiologist pleaded guilty to illegally supplying Aegerion Pharmaceuticals with information about his patients. Source: Drug Industry Daily

Continue ReadingCardiologist Pleads Guilty to Giving Aegerion Patient Information to Boost Prescriptions

McCaskill Bill Would Kill Tax Breaks for Direct-to-Consumer Drug Advertising

  • Post author:Sam
  • Post published:March 1, 2018
  • Post category:Drug Industry Daily

Sen. Claire McCaskill (D-Mo.) introduced legislation that would eliminate tax breaks for drugmakers that advertise directly to consumers. Source: Drug Industry Daily

Continue ReadingMcCaskill Bill Would Kill Tax Breaks for Direct-to-Consumer Drug Advertising

FDA Releases New Draft Guidance on DSCSA Tracking Standards, Definitions

  • Post author:Sam
  • Post published:March 1, 2018
  • Post category:Drug Industry Daily

The FDA issued two draft guidances aimed at implementing the Drug Supply Chain Security Act’s provisions for an electronic track-and-trace system for certain prescription drugs extending throughout the supply chain…

Continue ReadingFDA Releases New Draft Guidance on DSCSA Tracking Standards, Definitions

EMA Issues Revised Guidance on Biomarkers, Diagnostic Criteria for Alzheimer’s Medicines

  • Post author:Sam
  • Post published:February 28, 2018
  • Post category:Drug Industry Daily

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a revised guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease, focusing on the design…

Continue ReadingEMA Issues Revised Guidance on Biomarkers, Diagnostic Criteria for Alzheimer’s Medicines
  • Go to the previous page
  • 1
  • …
  • 258
  • 259
  • 260
  • 261
  • 262
  • 263
  • 264
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.